two hundred fifty-two previously untreated evaluable patients with multiple myeloma were entered into a study testing a regimen of three intravenous alkylating agents , melphalan , cyclophosphamide , and carmustine ( bcnu ) , given in combination ( bcmp ) against a regimen employing oral melphalan ( mp ) .
C0026764
multiple
C0010583
cyclophosphamide